Truist initiated coverage of Perspective Therapeutics with a Buy rating and $21 price target. Perspective is a radiopharma company focused on developing treatments for a broad range of cancers with a proprietary platform using a differentiated isotope, the analyst tells investors in a research note. The firm says the company’s two Phase 1 data readouts, one in neuroendocrine tumor and one in melanoma, in the second half of 2024 can potentially give platform validation and investor credit towards its pipeline. Perspective has an attractive pipeline of cancer targets with significant market opportunities, contends Truist.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics presents at World Molecular Imaging Congress
- Perspective Therapeutics granted Fast Track Designation for VMT01
- Perspective Therapeutics participates in a webinar with Cantor Fitzgerald
- Mark Austin Steps Down from Executive Roles at Perspective Therapeutics
- Perspective Therapeutics to Participate in Upcoming Investor Conferences in September